{'52WeekChange': 2.2452834,
 'SandP52WeekChange': None,
 'address1': '1460 Broadway',
 'address2': 'Suite 15044',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.8,
 'askSize': 2200,
 'averageDailyVolume10Day': 643575,
 'averageVolume': 1537136,
 'averageVolume10days': 643575,
 'beta': 2.232804,
 'beta3Year': None,
 'bid': 6.62,
 'bidSize': 800,
 'bookValue': 0.94,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 6.8299,
 'dayLow': 6.41,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.512,
 'enterpriseToRevenue': None,
 'enterpriseValue': 304138432,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 6.8415713,
 'fiftyTwoWeekHigh': 9.4,
 'fiftyTwoWeekLow': 1.74,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 33260357,
 'forwardEps': -1.29,
 'forwardPE': -5.131783,
 'fromCurrency': None,
 'fullTimeEmployees': 65,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.41026002,
 'heldPercentInstitutions': 0.33278,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ovidrx.com',
 'longBusinessSummary': 'Ovid Therapeutics Inc., a biopharmaceutical company, '
                        'develops impactful medicines for patients and '
                        'families with neurological disorders in the United '
                        'States. The company is developing OV101, a drug '
                        'candidate, which is in Phase III clinical trial for '
                        'the treatment of angelman syndrome in adults; and '
                        'completed Phase II clinical trial for the treatment '
                        'of fragile X syndrome in adolescent and young male '
                        'adults. It is also developing OV935, a drug '
                        'candidate, which is in a Phase II clinical trial for '
                        'the treatment of cyclin-dependent kinase-like 5 '
                        'deficiency disorder and dravet syndrome. In addition, '
                        'the company undertakes research programs exploring '
                        'OV329 in infantile spasm/rare epilepsies; and OV881 '
                        'as a microRNA gene therapy for the treatment of '
                        'angelman syndrome. Ovid Therapeutics Inc. has a '
                        'collaboration agreement with Takeda Pharmaceutical '
                        'Company Limited; a license agreement with H. Lundbeck '
                        'A/S; strategic research collaboration with Columbia '
                        'University Irving Medical Center; and license '
                        'agreement with Angelini Pharma to develop, '
                        'manufacture and commercialize OV101 for the treatment '
                        'of angelman syndrome in Europe. The company was '
                        'founded in 2014 and is headquartered in New York, New '
                        'York.',
 'longName': 'Ovid Therapeutics Inc.',
 'market': 'us_market',
 'marketCap': 362472128,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_288870432',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -66691136,
 'nextFiscalYearEnd': 1640908800,
 'open': 6.75,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '646 661 7661',
 'previousClose': 6.88,
 'priceHint': 2,
 'priceToBook': 7.042553,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 6.8299,
 'regularMarketDayLow': 6.41,
 'regularMarketOpen': 6.75,
 'regularMarketPreviousClose': 6.88,
 'regularMarketPrice': 6.75,
 'regularMarketVolume': 629006,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 54754100,
 'sharesPercentSharesOut': 0.066199996,
 'sharesShort': 3624093,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 844795,
 'shortName': 'Ovid Therapeutics Inc.',
 'shortPercentOfFloat': 0.0846,
 'shortRatio': 1.48,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'OVID',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.472,
 'twoHundredDayAverage': 4.426475,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '51982f47-ea34-3602-8b3b-2a8cb7696156',
 'volume': 629006,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.ovidrx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10036'}